S-Mephenytoin hydroxylation phenotypes in a Jordanian population*
- 1 November 1995
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 58 (5) , 542-547
- https://doi.org/10.1016/0009-9236(95)90174-4
Abstract
We tested the ability of 194 unrelated, healthy Jordanian volunteers to metabolize S-mephenytoin. Mephenytoin (100 mg) was coadministered with debrisoquin (10 mg) orally and urine was collected for 8 hours. Mephenytoin metabolism was tested according to three measures: the amount of 4-hydroxymephenytoin, the S/R enantiomeric ratio, and the presence of a polar, acid-labile metabolite in urine collected for 8 hours after the dose. The S/R ratio and the presence of the acid-labile metabolite were determined in the urine of 16 patients who had low amounts of 4-hydroxymephenytoin (log hydroxylation index > or = 1). On examination of these three parameters of oxidation status, nine subjects were found to be poor metabolizers of mephenytoin by all three parameters. Thus 4.6% (95% confidence interval of 1.6% to 7.6%) of Jordanian subjects studied were poor metabolizers of mephenytoin. According to the Hardy-Weinberg Law, the frequency of the recessive autosomal gene controlling the poor metabolizer status of mephenytoin was predicted to be 0.215% (95% confidence interval of 0.146% to 0.283%). These results are on the same order of magnitude as those determined in European white populations and constitute the first report in Arab populations.Keywords
This publication has 30 references indexed in Scilit:
- Polymorphism of Debrisoquine and Mephenytoin Hydroxylation among EstoniansBasic & Clinical Pharmacology & Toxicology, 1993
- The role of individual human cytochrpmes P450 in drug metabolism and clinical responseTrends in Pharmacological Sciences, 1992
- Polymorphism in stereoselective hydroxylations of mephenytoin and hexobarbital by Japanese liver samples in relation to cytochrome P-450 human-2 (IIC9)Xenobiotica, 1992
- The activation of the biguanide antimalarial proguanil co‐segregates with the mephenytoin oxidation polymorphism‐a panel study.British Journal of Clinical Pharmacology, 1991
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme.British Journal of Clinical Pharmacology, 1990
- Slow Omeprazole Metabolizers Are Also Poor S-Mephenytoin HydroxylatorsTherapeutic Drug Monitoring, 1990
- Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.British Journal of Clinical Pharmacology, 1989
- Confidence intervals rather than P values: estimation rather than hypothesis testing.BMJ, 1986
- Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1983